A new diabetes treatment that requires a single daily injection and lasts for 24 hours has been approved for limited prescriptions on the National Health Service. The diabetes drug helps to control diabetes amongst people with type 2 diabetes and is typically prescribed to overweight patients.
Victoza (liraglutide), manufactured by Novo Nordisk, has already been approved in the UK since July 2009. However, the National Institute for Health and Clinical Excellence took some time to review whether the drug is clinically effective and cost effective for type 2 diabetes patients.
NICE concluded that a single daily injection of Liraglutide could be given alongside two anti-diabetic medications. The treatment would specifically be for type 2 diabetes patients also suffering from obesity. As well as helping patients to control and lower blood glucose levels, the diabetes drug also suppresses the appetite of users.
What's new on the forum? ⭐️
Get our free newsletters
Stay up to date with the latest news, research and breakthroughs.